The role of transporters in the toxicity of nucleoside and nucleotide analogs

Expert Opinion on Drug Metabolism and Toxicology

Volumn 8, Issue 6, 2012, Pages 665-676

  Koczor, Christopher A ^a   Torres, Rebecca A ^a   Lewis, William ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anticancer; Antiretroviral; Antiviral; Mitochondria; Nucleoside analogs; Nucleoside transporters

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ABACAVIR; ABC TRANSPORTER; ACICLOVIR; ADEFOVIR; ADENINE NUCLEOTIDE DERIVATIVE; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; AZACITIDINE; CIDOFOVIR; CLADRIBINE; CLOFARABINE; CYTARABINE; DIDANOSINE; EMTRICITABINE; ENTECAVIR; FAMCICLOVIR; FLUDARABINE; GANCICLOVIR; GEMCITABINE; LAMIVUDINE; MULTIDRUG RESISTANCE PROTEIN; NUCLEOSIDE ANALOG; NUCLEOSIDE TRANSPORTER; STAVUDINE; TELBIVUDINE; TENOFOVIR; UNINDEXED DRUG; VALACICLOVIR; ZIDOVUDINE;

ACUTE KIDNEY FAILURE; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ANEMIA; B CELL LEUKEMIA; B CELL LMYPHOCYTIC LEUKEMIA; B CELL LYMPHOMA; BONE MARROW SUPPRESSION; BREAST CANCER; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC MYELOMONOCYTIC LEUKEMIA; CYTOMEGALOVIRUS INFECTION; CYTOTOXICITY; FANCONI RENOTUBULAR SYNDROME; GENETIC POLYMORPHISM; HAIRY CELL LEUKEMIA; HEART INFARCTION; HEMOLYTIC ANEMIA; HEPATITIS B; HEPATOBILIARY DISEASE; HEPATOMEGALY; HERPES SIMPLEX; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERSENSITIVITY REACTION; KIDNEY DISEASE; KIDNEY FAILURE; KINETICS; LACTIC ACIDOSIS; LIVER DISEASE; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MOLECULE; MYELODYSPLASTIC SYNDROME; MYOPATHY; NEPHROTOXICITY; NEUROLOGIC DISEASE; NEUTROPENIA; OVARY CANCER; PANCREAS CANCER; PANCREATITIS; PERIPHERAL NEUROPATHY; PROTEIN EXPRESSION; REVIEW; STEATOSIS; STOMATITIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; TOXICITY;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; BIOLOGICAL TRANSPORT; HUMANS; NUCLEOSIDE TRANSPORT PROTEINS; NUCLEOSIDES; NUCLEOTIDE TRANSPORT PROTEINS; NUCLEOTIDES;

EID: 84862093698     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2012.680885     Document Type: Review

References (89)

1. Koczor CA, Lewis W. Nucleoside reverse transcriptase inhibitor toxicity and mitochondrial DNA. Expert Opin Drug Metab Toxicol 2010;6(12):1493-504
2. Razonable RR. Antiviral drugs for viruses other than human immunodeficiency virus. Mayo Clin Proc 2011;86(10):1009-26
3. Galmarini CM, Jordheim L, Dumontet C. Pyrimidine nucleoside analogs in cancer treatment. Expert Rev Anticancer Ther 2003;3(5):717-28 (Pubitemid 37337110)
4. Leung GP, Tse CM. The role of mitochondrial and plasma membrane nucleoside transporters in drug toxicity. Expert Opin Drug Metab Toxicol 2007;3(5):705-18 (Pubitemid 351320638)
5. Burckhardt G, Burckhardt BC. In vitro and in vivo evidence of the importance of organic anion transporters (OATs) in drug therapy. Handb Exp Pharmacol 2011;201:29-104
6. Ciarimboli G. Role of organic cation transporters in drug-induced toxicity. Expert Opin Drug Metab Toxicol 2011;7(2):159-74
7. Huber-Ruano I, Pastor-Anglada M. Transport of nucleoside analogs across the plasma membrane: a clue to understanding drug-induced cytotoxicity. Curr Drug Metab 2009;10(4):347-58
8. Young JD, Yao SY, Sun L, et al. Human equilibrative nucleoside transporter (ENT) family of nucleoside and nucleobase transporter proteins. Xenobiotica 2008;38(7-8):995-1021
9. Griffiths M, Beaumont N, Yao SY, et al. Cloning of a human nucleoside transporter implicated in the cellular uptake of adenosine and chemotherapeutic drugs. Nat Med 1997;3(1):89-93 (Pubitemid 27019148)
10. Griffiths M, Yao SY, Abidi F, et al. Molecular cloning and characterization of a nitrobenzylthioinosine-insensitive (ei) equilibrative nucleoside transporter from human placenta. Biochem J 1997;328(Pt 3):739-43 (Pubitemid 28005769)
11. King KM, Damaraju VL, Vickers MF, et al. A comparison of the transportability, and its role in cytotoxicity, of clofarabine, cladribine, and fludarabine by recombinant human nucleoside transporters produced in threemodel expression systems. Mol Pharmacol 2006;69(1):346-53 (Pubitemid 43048921)
12. Mackey JR, Mani RS, Selner M, et al. Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res 1998;58(19):4349-57 (Pubitemid 28450036)
13. Baldwin SA, Yao SY, Hyde RJ, et al. Functional characterization of novel human and mouse equilibrative nucleoside transporters (hENT3 and mENT3) located in intracellular membranes. J Biol Chem 2005;280(16):15880-7 (Pubitemid 40616710)
14. Crawford CR, Patel DH, Naeve C, et al. Cloning of the human equilibrative, nitrobenzylmercaptopurine riboside (NBMPR)-insensitive nucleoside transporter ei by functional expression in a transport-deficient cell line. J Biol Chem 1998;273(9):5288-93 (Pubitemid 28108694)
15. Barnes K, Dobrzynski H, Foppolo S, et al. Distribution and functional characterization of equilibrative nucleoside transporter-4, a novel cardiac adenosine transporter activated at acidic pH. Circ Res 2006;99(5):510-19 (Pubitemid 44337823)
16. Lai Y, Tse CM, Unadkat JD. Mitochondrial expression of the human equilibrative nucleoside transporter 1 (hENT1) results in enhanced mitochondrial toxicity of antiviral drugs. J Biol Chem 2004;279(6):4490-7 (Pubitemid 38199039)
17. Mani RS, Hammond JR, Marjan JM, et al. Demonstration of equilibrative nucleoside transporters (hENT1 and hENT2) in nuclear envelopes of cultured human choriocarcinoma (BeWo) cells by functional reconstitution in proteoliposomes. J Biol Chem 1998;273(46):30818-25 (Pubitemid 28545567)
18. Yao SY, Ng AM, Sundaram M, et al. Transport of antiviral 3′-deoxy-nucleoside drugs by recombinant human and rat equilibrative, nitrobenzylthioinosine (NBMPR)-insensitive (ENT2) nucleoside transporter proteins produced in Xenopus oocytes. Mol Membr Biol 2001;18(2):161-7 (Pubitemid 32666795)
19. Vickers MF, Zhang J, Visser F, et al. Uridine recognition motifs of human equilibrative nucleoside transporters 1 and 2 produced in Saccharomyces cerevisiae. Nucleosides Nucleotides Nucleic Acids 2004;23(1-2):361-73 (Pubitemid 38351985)
20. Yamamoto T, Kuniki K, Takekuma Y, et al. Ribavirin uptake by cultured human choriocarcinoma (BeWo) cells and Xenopus laevis oocytes expressing recombinant plasma membrane human nucleoside transporters. Eur J Pharmacol 2007;557(1):1-8 (Pubitemid 46135552)
21. Pastor-Anglada M, Cano-Soldado P, Errasti-Murugarren E, et al. SLC28 genes and concentrative nucleoside transporter (CNT) proteins. Xenobiotica 2008;38(7-8):972-94
22. Ritzel MW, Yao SY, Huang MY, et al. Molecular cloning and functional expression of cDNAs encoding a human Na+-nucleoside cotransporter (hCNT1). Am J Physiol 1997;272(2 Pt 1):C707-14
23. Ritzel MW, Yao SY, Ng AM, et al. Molecular cloning, functional expression and chromosomal localization of a cDNA encoding a human Na+/ nucleoside cotransporter (hCNT2) selective for purine nucleosides and uridine. Mol Membr Biol 1998;15(4):203-11 (Pubitemid 29097592)
24. Ritzel MW, Ng AM, Yao SY, et al. Molecular identification and characterization of novel human and mouse concentrative Na+-nucleoside cotransporter proteins (hCNT3 and mCNT3) broadly selective for purine and pyrimidine nucleosides (system cib). J Biol Chem 2001;276(4):2914-27
25. Gutierrez MM, Giacomini KM. Substrate selectivity, potential sensitivity and stoichiometry of Na(+)-nucleoside transport in brush border membrane vesicles from human kidney. Biochim Biophys Acta 1993;1149(2):202-8 (Pubitemid 23197676)
26. Flanagan SA, Meckling-Gill KA. Characterization of a novel Na+-dependent, guanosine-specific, nitrobenzylthioinosine-sensitive transporter in acute promyelocytic leukemia cells. J Biol Chem 1997;272(29):18026-32 (Pubitemid 27306382)
27. Flanagan SA, Gandhi V, Secrist JA III, et al. The novel nucleoside transport system exhibited by NB4 cells, csg, transports deoxyguanosine analogues, including ara-G. Biochem Pharmacol 2003;66(5):733-7 (Pubitemid 37011411)
28. Cano-Soldado P, Lorrayoz IM, Molina-Arcas M, et al. Interaction of nucleoside inhibitors of HIV-1 reverse transcriptase with the concentrative nucleoside transporter-1 (SLC28A1). Antivir Ther 2004;9(6):993-1002 (Pubitemid 40040273)
29. Graham KA, Leithoff J, Coe IR, et al. Differential transport of cytosine-containing nucleosides by recombinant human concentrative nucleoside transporter protein hCNT1. Nucleosides Nucleotides Nucleic Acids 2000;19(1-2):415-34 (Pubitemid 30230051)
30. Zhang L, Dresser MJ, Gray AT, et al. Cloning and functional expression of a human liver organic cation transporter. Mol Pharmacol 1997;51(6):913-21 (Pubitemid 27249124)
31. Gorboulev V, Ulzheimer JC, Akhoundova A, et al. Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol 1997;16(7):871-81 (Pubitemid 27332696)
32. Nies AT, Koepsell H, Winter S, et al. Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver. Hepatology 2009;50(4):1227-40
33. VanWert AL, Gionfriddo MR, Sweet DH. Organic anion transporters: discovery, pharmacology, regulation and roles in pathophysiology. Biopharm Drug Dispos 2010;31(1):1-71
34. Jung N, Lehmann C, Rubbert A, et al. Relevance of the organic cation transporters 1 and 2 for antiretroviral drug therapy in human immunodeficiency virus infection. Drug Metab Dispos 2008;36(8):1616-23
35. Borst P, Balzarini J, Ono N, et al. The potential impact of drug transporters on nucleoside-analog-based antiviral chemotherapy. Antiviral Res 2004;62(1):1-7 (Pubitemid 38340742)
36. Schinkel AH, Jonker JW. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev 2003;55(1):3-29 (Pubitemid 36078452)
37. Schuetz JD, Connelly MC, Sun D, et al. MRP4: a previously unidentified factor in resistance to nucleoside-based antiviral drugs. Nat Med 1999;5(9):1048-51 (Pubitemid 29439577)
38. Cascorbi I. P-glycoprotein: tissue distribution, substrates, and functional consequences of genetic variations. Handb Exp Pharmacol 2011;201:261-83
39. Miller DS. Regulation of P-glycoprotein and other ABC drug transporters at the blood-brain barrier. Trends Pharmacol Sci 2010;31(6):246-54
40. Marquez B, Van Bambeke F. ABC multidrug transporters: target for modulation of drug pharmacokinetics and drug-drug interactions. Curr Drug Targets 2011;12(5):600-20
41. Ishikawa T, Nakagawa H. Human ABC transporter ABCG2 in cancer chemotherapy and pharmacogenomics. J Exp Ther Oncol 2009;8(1):5-24
42. Robey RW, Ierano C, Zhan Z, et al. The challenge of exploiting ABCG2 in the clinic. Curr Pharm Biotechnol 2011;12(4):595-608
43. Keppler D. Multidrug resistance proteins (MRPs, ABCCs): importance for pathophysiology and drug therapy. Handb Exp Pharmacol 2011;201:299-323
44. Russel FG, Koenderink JB, Masereeuw R. Multidrug resistance protein 4 (MRP4/ABCC4): a versatile efflux transporter for drugs and signaling molecules. Trends Pharmacol Sci 2008;29(4):200-7
45. Kohler JJ, Hosseini SH, Hoying-Brandt A, et al. Tenofovir renal toxicity targets mitochondria of renal proximal tubules. Lab Invest 2009;89(5):513-19
46. Kohler JJ, Hosseini SH, Cucoranu I, et al. Murine cardiac mtDNA: effects of transgenic manipulation of nucleoside phosphorylation. Lab Invest 2009;89(2):122-30
47. Kohler JJ, Hosseini SH, Green E, et al. Cardiac-targeted transgenic mutant mitochondrial enzymes: mtDNA defects, antiretroviral toxicity and cardiomyopathy. Cardiovasc Toxicol 2008;8(2):57-69
48. Kohler JJ, Hosseini SH, Lewis W. Mitochondrial DNA impairment in nucleoside reverse transcriptase inhibitor-associated cardiomyopathy. Chem Res Toxicol 2008;21(5):990-6
49. Lewis W, Day BJ, Kohler JJ, et al. Decreased mtDNA, oxidative stress, cardiomyopathy, and death from transgenic cardiac targeted human mutant polymerase gamma. Lab Invest 2007;87(4):326-35 (Pubitemid 46474566)
50. Lewis W, Day BJ, Copeland WC. Mitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspective. Nat Rev Drug Discov 2003;2(10):812-22 (Pubitemid 37361813)
51. Lewis W, Dalakas MC. Mitochondrial toxicity of antiviral drugs. Nat Med 1995;1(5):417-22
52. Kohler JJ, Cucoranu I, Fields E, et al. Transgenic mitochondrial superoxide dismutase and mitochondrially targeted catalase prevent antiretroviral-induced oxidative stress and cardiomyopathy. Lab Invest 2009;89(7):782-90
53. Lewis W, Haase CP, Miller YK, et al. Transgenic expression of the deoxynucleotide carrier causes mitochondrial damage that is enhanced by NRTIs for AIDS. Lab Invest 2005;85(8):972-81 (Pubitemid 41486422)
54. Lewis W, Kohler JJ, Hosseini SH, et al. Antiretroviral nucleosides, deoxynucleotide carrier and mitochondrial DNA: evidence supporting the DNA pol gamma hypothesis. AIDS 2006;20(5):675-84 (Pubitemid 43884294)
55. Lam W, Chen C, Ruan S, et al. Expression of deoxynucleotide carrier is not associated with the mitochondrial DNA depletion caused by anti-HIV dideoxynucleoside analogs and mitochondrial dNTP uptake. Mol Pharmacol 2005;67(2):408-16 (Pubitemid 40216733)
56. Robak T, Blonski JZ, Kasznicki M, et al. Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial. Blood 2000;96(8):2723-9
57. Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000;343(24):1750-7
58. Begleiter A, Verburg L, Ashique A, et al. Comparison of antitumor activities of 2-chlorodeoxyadenosine and 9-betaarabinosyl- 2-fluoroadenine in chronic lymphocytic leukemia and marrow cells in vitro. Leukemia 1995;9(11):1875-81
59. Robak T. Cladribine in the treatment of chronic lymphocytic leukemia. Leuk Lymphoma 2001;40(5-6):551-64 (Pubitemid 32303246)
60. Leeds JM, Slabaugh MB, Mathews CK. DNA precursor pools and ribonucleotide reductase activity: distribution between the nucleus and cytoplasm of mammalian cells. Mol Cell Biol 1985;5(12):3443-50 (Pubitemid 16233051)
61. Shewach DS, Daddona PE, Ashcraft E, et al. Metabolism and selective cytotoxicity of 9-beta-Darabinofuranosylguanine in human lymphoblasts. Cancer Res 1985;45(3):1008-14 (Pubitemid 15111252)
62. Verhoef V, Fridland A. Metabolic basis of arabinonucleoside selectivity for human leukemic T- and B-lymphoblasts. Cancer Res 1985;45(8):3646-50 (Pubitemid 15226439)
63. Cote HC, Magil AB, Harris M, et al. Exploring mitochondrial nephrotoxicity as a potential mechanism of kidney dysfunction among HIV-infected patients on highly active antiretroviral therapy. Antivir Ther 2006;11(1):79-86
64. Vidal F, Domingo JC, Guallar J, et al. In vitro cytotoxicity and mitochondrial toxicity of tenofovir alone and in combination with other antiretrovirals in human renal proximal tubule cells. Antimicrob Agents Chemother 2006;50(11):3824-32 (Pubitemid 44684899)
65. Kohler JJ, Hosseini SH. Subcellular renal proximal tubular mitochondrial toxicity with tenofovir treatment. Methods Mol Biol 2011;755:267-77
66. Cihlar T, Ho ES, Lin DC, et al. Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs. Nucleosides Nucleotides Nucleic Acids 2001;20(4-7):641-8 (Pubitemid 32821831)
67. Nagle MA, Truong DM, Dnyanmote AV, et al. Analysis of three-dimensional systems for developing and mature kidneys clarifies the role of OAT1 and OAT3 in antiviral handling. J Biol Chem 2011;286(1):243-51
68. Leggas M, Adachi M, Scheffer GL, et al. Mrp4 confers resistance to topotecan and protects the brain from chemotherapy. Mol Cell Biol 2004;24(17):7612-21 (Pubitemid 39121487)
69. Kohler JJ, Hosseini SH, Green E, et al. Tenofovir renal proximal tubular toxicity is regulated by OAT1 and MRP4 transporters. Lab Invest 2011;91(6):852-8
70. Ray AS, Cihlar T, Robinson KL, et al. Mechanism of active renal tubular efflux of tenofovir. Antimicrob Agents Chemother 2006;50(10):3297-304 (Pubitemid 44527501)
71. Reilly KM, Kisor DF. Profile of nelarabine: use in the treatment of T-cell acute lymphoblastic leukemia. Oncol Targets Ther 2009;2:219-28
72. Kurtzberg J, Ernst TJ, Keating MJ, et al. Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies. J Clin Oncol 2005;23(15):3396-403
73. Homminga I, Zwaan CM, Manz CY, et al. In vitro efficacy of forodesine and nelarabine (ara-G) in pediatric leukemia. Blood 2011;118(8):2184-90
74. Fyrberg A, Peterson C, Kagedal B, et al. Induction of fetal hemoglobin and ABCB1 gene expression in 9-beta-Darabinofuranosylguanine- resistant MOLT-4 cells.Cancer Chemother Pharmacol 2011;68(3):583-91
75. Lowenberg B, Pabst T, Vellenga E, et al. Cytarabine dose for acute myeloid leukemia. N Engl J Med 2011;364(11):1027-36
76. Parmar S, Seeringer A, Denich D, et al. Variability in transport and biotransformation of cytarabine is associated with its toxicity in peripheral blood mononuclear cells. Pharmacogenomics 2011;12(4):503-14
77. Hopper-Borge EA, Churchill T, Paulose C, et al. Contribution of Abcc10 (Mrp7) to in vivo paclitaxel resistance as assessed in Abcc10(-/-) mice. Cancer Res 2011;71(10):3649-57
78. van den Heuvel-Eibrink MM, Wiemer EA, Prins A, et al. Increased expression of the breast cancer resistance protein (BCRP) in relapsed or refractory acute myeloid leukemia (AML). Leukemia 2002;16(5):833-9 (Pubitemid 34537555)
79. Hampras SS, Sucheston L, Weiss J, et al. Genetic polymorphisms of ATP-binding cassette (ABC) proteins, overall survival and drug toxicity in patients with Acute Myeloid Leukemia. Int J Mol Epidemiol Genet 2010;1(3):201-7
80. de Wolf C, Jansen R, Yamaguchi H, et al. Contribution of the drug transporter ABCG2 (breast cancer resistance protein) to resistance against anticancer nucleosides. Mol Cancer Ther 2008;7(9):3092-102
81. Ward JL, Sherali A, Mo ZP, et al. Kinetic and pharmacological properties of cloned human equilibrative nucleoside transporters, ENT1 and ENT2, stably expressed in nucleoside transporter-deficient PK15 cells. Ent2 exhibits a low affinity for guanosine and cytidine but a high affinity for inosine. J Biol Chem 2000;275(12):8375-81 (Pubitemid 30180179)
82. Cundy KC, Li ZH, Lee WA. Effect of probenecid on the distribution, metabolism, and excretion of cidofovir in rabbits. Drug Metab Dispos 1996;24(3):315-21 (Pubitemid 26087085)
83. Lacy SA, Hitchcock MJ, Lee WA, et al. Effect of oral probenecid coadministration on the chronic toxicity and pharmacokinetics of intravenous cidofovir in cynomolgus monkeys. Toxicol Sci 1998;44(2):97-106 (Pubitemid 28415221)
84. Rabascio C, Laszlo D, Andreola G, et al. Expression of the human concentrative nucleotide transporter 1 (hCNT1) gene correlates with clinical response in patients affected by Waldenstrom's Macroglobulinemia (WM) and small lymphocytic lymphoma (SLL) undergoing a combination treatment with 2-chloro-2'-deoxyadenosine (2-CdA) and Rituximab. Leuk Res2010;34(4):454-7
85. Nagai S, Takenaka K, Nachagari D, et al. Deoxycytidine kinase modulates the impact of the ABC transporterABCG2 on clofarabine cytotoxicity. Cancer Res 2011;71(5):1781-91
86. Guallar JP, Cano-Soldado P, Aymerich I, et al. Altered expression of nucleoside transporter genes (SLC28 and SLC29) in adipose tissue from HIV-1-infected patients. Antivir Ther 2007;12(6):853-63 (Pubitemid 47492555)
87. Wong A, Soo RA, Yong WP, et al. Clinical pharmacology and pharmacogenetics of gemcitabine. Drug Metab Rev 2009;41(2):77-88
88. Drugs@FDA.gov. U.S. Food and Drug Administration Website. Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/ [Accessed January 2012]
89. NCI Drug Dictionary. National Cancer Institute at the National Institutes of Health Website. Available from: http://www.cancer.gov/drugdictionary/ [Accessed January 2012]